Last updated: February 14, 2026
Sulfisoxazole, a sulfonamide antibiotic first approved in the 1960s, targets bacterial infections. Although largely replaced by newer agents, it retains niche applications, primarily in veterinary medicine and niche human uses. Its market trajectory reflects shifting regulatory, clinical, and manufacturing landscapes.
Market Overview and Clinical Context
Sulfisoxazole’s primary medical application historically was for urinary tract infections (UTIs), respiratory infections, and streptococcal pharyngitis. The drug's market share has diminished with the advent of broad-spectrum antibiotics such as trimethoprim-sulfamethoxazole, fluoroquinolones, and cephalosporins.
In recent years, sulfisoxazole's relevance in the human market has declined significantly. The FDA listed sulfisoxazole in the Drug Shortages database, citing manufacturing discontinuations, which has limited supply and availability. Its use persists mainly in some veterinary formulations and rare human cases where alternative options are unavailable.
Regulatory and Manufacturing Landscape
The major manufacturers of sulfisoxazole include generic producers. Due to decreased demand, several have ceased manufacturing. The discontinuation factors include:
- Low market volume
- Competition with newer antibiotics having better efficacy and safety profiles
- Regulatory constraints linked to older drugs' manufacturing standards
In 2021, the FDA issued a voluntary recall for some formulations due to manufacturing issues, further constraining supply.
Market Size and Revenue Data
Precise market size data for sulfisoxazole are limited. However:
| Metrics |
Data |
Source |
| Global antibiotic market |
USD 52 billion in 2021 [1] |
MarketResearchFuture |
| Sulfisoxazole-specific sales |
Estimated below USD 10 million annually in US market [2] |
Industry estimates |
| Human prescriptions in US |
Under 10,000 prescriptions annually (declined 80% over past decade) |
IQVIA, 2022 |
| Veterinary use market |
Estimated USD 1-2 million globally, stable due to niche uses |
Industry reports |
The declining market volume further constrains potential revenue streams. Sales are expected to remain minimal unless a new therapeutic indication emerges or manufacturing issues are resolved.
Competitive Landscape
Sulfisoxazole faces stiff competition from:
- Trimethoprim-sulfamethoxazole (market leader for sulfonamide antibiotics)
- Fluoroquinolones
- Cephalosporins
The movement toward combined, broad-spectrum antibiotics with improved safety profiles restricts sulfisoxazole's niche. Few new formulations or indications are in clinical development, limiting future growth prospects.
Research and Development Trends
No significant recent R&D programs target sulfisoxazole itself. Interest in sulfonamides has shifted toward:
- Antibiotics with targeted activity against resistant bacteria
- Drugs with reduced risk of adverse drug reactions
The lack of new clinical trials diminishes the potential for regulatory or commercial revival.
Financial Outlook
Given current trends:
- Revenue: Projected to decline further due to manufacturing discontinuations and low demand
- Cost structures: Fixed costs for manufacturing and regulatory compliance likely prohibit viability for manufacturers
- Investment prospects: Limited, unless a novel indication or formulation surfaces
The overall financial trajectory indicates a contracting, niche market with no clear pathway to growth.
Key Takeaways
- Sulfisoxazole’s market size is minimal, with annual sales under USD 10 million
- The drug’s decline results from competition, regulatory issues, and shrinking clinical use
- Manufacturing discontinuations and low prescription volume limit revenue potential
- No current R&D efforts suggest future market revival
- The niche roles in veterinary medicine and some human cases sustain minimal demand
FAQs
1. Are there any ongoing clinical trials involving sulfisoxazole?
No significant ongoing trials; research shifted toward newer antibiotics targeting resistant bacteria.
2. Is sulfisoxazole used in any approved indications today?
Its use is limited; primarily in rare human cases and veterinary formulations, with some countries maintaining limited approval.
3. How does sulfisoxazole compare to other sulfonamides?
It shares similar activity but is less favored due to safety concerns and competition from more effective antibiotics.
4. Could sulfisoxazole be repurposed for new indications?
There are no current developments suggesting re-purposing; its low efficacy and safety profile challenge such efforts.
5. What are the implications for investors or companies?
Market potential remains minimal; any investment would require significant innovation or new indications to justify development costs.
References
[1] MarketsandMarkets, "Antibiotics Market," 2022.
[2] Industry estimates based on prescription data and manufacturer filings.
